Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer E P, Flanagan R J
The State Hospital, Carstairs, Lanark, UK.
J Psychopharmacol. 2009 Mar;23(2):206-10. doi: 10.1177/0269881108089819. Epub 2008 May 30.
Patients may fail to respond to clozapine treatment despite use of the maximum licensed UK dosage (900 mg/day) because of ultra-rapid metabolism of the drug. We present the findings of a study of a national clozapine/norclozapine assay service for the period 1997-2005 and three individual case studies of patients treated with clozapine in doses greater than 900 mg/day. Clinicians should be alert to the possibility of treatment failure because of rapid clozapine clearance secondary to genetic factors and heavy cigarette consumption. This may necessitate the use of clozapine in doses up to 1400 mg/day, notably in young male smokers. Doses of greater than 900 mg/day are rarely justified in women. Anyone given relatively high-dose clozapine (600 mg/day or more) should be monitored regularly for adverse events and changes in smoking habit.
尽管使用了英国许可的最大剂量(900毫克/天),但由于药物的超快速代谢,患者可能对氯氮平治疗无反应。我们展示了一项针对1997年至2005年全国氯氮平/去甲氯氮平检测服务的研究结果,以及三个接受剂量大于900毫克/天氯氮平治疗患者的个案研究。临床医生应警惕由于遗传因素和大量吸烟导致氯氮平快速清除而引起治疗失败的可能性。这可能需要使用高达1400毫克/天的氯氮平剂量,尤其是在年轻男性吸烟者中。大于900毫克/天的剂量在女性中很少有正当理由。任何接受相对高剂量氯氮平(600毫克/天或更高)治疗的人都应定期监测不良事件和吸烟习惯的变化。